CUTANEOUS MELANOMA

This study tested a personalized vaccine made from each patient's own melanoma mutations. The goal was to see if it is safe and possible to create such a vaccine. Fifteen people with advanced melanoma received the vaccine, and researchers checked for side effects and immune respo…

This study tested the drug nivolumab in 26 people with stage IIB or IIC melanoma that had been completely removed by surgery. The goal was to see if nivolumab, an immunotherapy that helps the immune system attack cancer cells, could prevent the melanoma from coming back. Particip…

This early-phase trial tested a new personalized therapy called TBio-4101 for people with advanced melanoma that had stopped responding to standard treatments. The therapy uses a patient's own tumor-fighting immune cells, which are collected, multiplied in the lab, and then infus…

This study tested whether adding denosumab (a bone-strengthening drug) to standard immunotherapy (pembrolizumab or nivolumab) could help control advanced melanoma that has spread. Researchers enrolled 25 adults with stage III or IV melanoma who had not received prior immunotherap…

This study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment…

This study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination keeps cancer away longer…

This Phase 2 trial tested a modified polio virus called lerapolturev, alone or combined with an immunotherapy drug, in 27 adults with advanced melanoma that had stopped responding to standard PD-1 therapy. The virus was injected directly into tumors to trigger an immune attack. R…

This study tested whether an artificial intelligence (AI) system can help detect melanoma, a dangerous form of skin cancer. Researchers took photos of suspicious skin spots from 105 adults using a smartphone camera and let the AI analyze them. They compared the AI's results to di…

This completed study examined 127 melanoma patients to understand how the IL4I1 enzyme influences disease progression and resistance to treatments like immunotherapy and targeted therapy. Researchers analyzed blood and tumor tissue samples before and after treatment. The goal was…

This study looked at whether a special training program could help primary care doctors better spot and treat early-stage skin cancer, especially melanoma. Fifty-four doctors from two clinics took part. The training aimed to improve their knowledge and skills in identifying suspi…

This study looked at 73 people with many moles to see if certain mole features can help predict who is most likely to develop melanoma. Participants gave saliva samples and had their moles photographed and analyzed. The goal is to improve risk assessment and make melanoma screeni…

This completed study examined whether healthy skin near a melanoma tumor contains hidden cancer stem cells that might predict the disease's return. Researchers analyzed tissue from 226 people with early-stage melanoma to see if these cells are linked to 5-year survival. The goal …

This study tested a method to identify immune cells (T cells) that recognize unique mutations in tumors. Researchers took blood and lymph node samples from 25 patients with breast cancer or melanoma. The goal was to see if they could find and measure these cancer-specific immune …